JERSEY CITY, N.J., Jan. 30, 2025 — Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved Avtozma® (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and subcutaneous (SC) formulation as a biosimilar to…Original Article
FDA Approves Avtozma (tocilizumab-anoh), a Biosimilar to Actemra
